Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05659589

Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury

Led by Centre Hospitalier Universitaire, Amiens · Updated on 2025-05-28

105

Participants Needed

1

Research Sites

180 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Acute kidney injury (AKI) is a frequent disease in conventional hospital departments and in intensive care units. It's associated with a high risk to develop chronic kidney disease (CKD), even after a single small AKI episode. It's also associated with an important morbi-mortality, particularly cardiovascular (CV). Some studies have already showed a link between AKI and CV risk but pathologic mechanisms implicated are still unknown. In AKI and CKD, numerous substances, called uremic toxins (UT) are accumulating in blood. In CKD, those toxins, and particularly Indoxyl sulfate (IS), are known to have cardiac and vascular deleterious consequences. However, in AKI, whether acute accumulation of UT may trigger CV complications is unknown. The purpose of this study is that during AKI, a high UT concentration, in particular IS, would be associated with early vascular and cardiac dysfunctions that can be characterized by the persistence of an accelerated pulse wave velocity (PWV). The main objective is to evaluate the correlation between UT concentrations (especially IS) and arterial stiffness (PWV measurement) at three months of an AKI episode in conventional hospital departments and in the intensive care unit of nephrology.

CONDITIONS

Official Title

Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age over 18 years old.
  • Patients hospitalized in conventional hospital departments and in intensive care units of nephrology.
  • Patients with moderate to severe AKI (KDIGO 2 or 3) without dialysis.
  • AKI from functional or organic aetiology
Not Eligible

You will not qualify if you...

  • Patients with severe CKD (GFR<45ml/min/1.73 m2) or with kidney transplants.
  • Patients with AKI from septic or obstructive aetiology.
  • Patients with AKI from toxic aetiology whose toxic would be also responsible for cardiac toxicity.
  • Patients with sepsis or blood inflammation.
  • Patients with severe chronic cardiac dysfunction.
  • Patients with arrhythmia or complete heart block.
  • Patients with peripheral artery occlusive disease.
  • Pregnancy.
  • Patients on palliative care.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Amiens hospital

Amiens, France, 80000

Actively Recruiting

Loading map...

Research Team

P

Pauline Caillard, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

NON_RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here